Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
Provided By PR Newswire
Last update: Aug 7, 2025
Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten offering with expected cash runway into 2029
Read more at prnewswire.com
